NEW YORK (GenomeWeb News) – Cancer Genetics has filed a preliminary prospectus to offer $15 million in a public offering of its stock.

In a Form S-1 filed with the US Securities and Exchange Commission on Wednesday, the Rutherford, NJ-based cancer diagnostics firm said that it anticipates net proceeds of $13.5 million from the offering. It has not priced the shares or said how many shares it plans to offer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.